Dogwood Therapeutics (NASDAQ:DWTX – Get Free Report) issued its earnings results on Thursday. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02, FiscalAI reports. The business had revenue of $0.10 million for the quarter.
Dogwood Therapeutics Price Performance
NASDAQ:DWTX traded up $0.24 during midday trading on Friday, reaching $1.28. 171,530 shares of the company traded hands, compared to its average volume of 78,791. Dogwood Therapeutics has a twelve month low of $0.90 and a twelve month high of $7.04. The firm has a market capitalization of $48.93 million, a price-to-earnings ratio of -0.14 and a beta of 2.08. The company has a fifty day moving average price of $1.56 and a 200 day moving average price of $1.96.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Thursday, October 22nd. HC Wainwright reiterated a “buy” rating on shares of Dogwood Therapeutics in a research note on Wednesday, September 2nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Dogwood Therapeutics currently has an average rating of “Hold” and a consensus price target of $12.00.
Dogwood Therapeutics Company Profile
Dogwood Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with viral activation. The company’s programs are designed to address conditions for which persistent or reactivated viral activity may contribute to symptoms and disease progression.
Its lead investigational product, IMC-1, is an oral combination of the antiviral drug famciclovir and the anti-inflammatory drug celecoxib. The company has evaluated IMC-1 in fibromyalgia and has also investigated its potential use in other conditions, including symptoms associated with long COVID.
Featured Stories
- Five stocks we like better than Dogwood Therapeutics
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Dogwood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dogwood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
